Fundamental Analysis of ORAGENICS INC(NYSEARCA:OGEN) stock

Fundamental Rating

Taking everything into account, OGEN scores 0 out of 10 in our fundamental rating. OGEN was compared to 568 industry peers in the Biotechnology industry. OGEN may be in some trouble as it scores bad on both profitability and health. OGEN has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

OGEN had negative earnings in the past year.

OGEN had a negative operating cash flow in the past year.

In the past 5 years OGEN always reported negative net income.

OGEN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

OGEN has a worse Return On Assets (-383.66%) than 96.81% of its industry peers.

With a Return On Equity value of -648.76%, OGEN is not doing good in the industry: 81.77% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-383.66%
ROE	-648.76%
ROIC	N/A

ROA(3y)-189.46%

ROA(5y)-157.74%

ROE(3y)-273.71%

ROE(5y)-213.69%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OGEN so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

OGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, OGEN has more shares outstanding

Compared to 5 years ago, OGEN has more shares outstanding

Compared to 1 year ago, OGEN has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -68.49, we must say that OGEN is in the distress zone and has some risk of bankruptcy.

OGEN has a worse Altman-Z score (-68.49) than 96.11% of its industry peers.

A Debt/Equity ratio of 0.17 indicates that OGEN is not too dependend on debt financing.

OGEN's Debt to Equity ratio of 0.17 is on the low side compared to the rest of the industry. OGEN is outperformed by 67.96% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.17
Debt/FCF	N/A
Altman-Z	-68.49

ROIC/WACCN/A

WACC11.44%

2.3 Liquidity

OGEN has a Current Ratio of 1.93. This is a normal value and indicates that OGEN is financially healthy and should not expect problems in meeting its short term obligations.

With a Current ratio value of 1.93, OGEN is not doing good in the industry: 76.11% of the companies in the same industry are doing better.

A Quick Ratio of 1.93 indicates that OGEN should not have too much problems paying its short term obligations.

Looking at the Quick ratio, with a value of 1.93, OGEN is doing worse than 74.16% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.93
Quick Ratio	1.93

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

OGEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -36.18%.

Looking at the last year, OGEN shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.

EPS 1Y (TTM)-36.18%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%55.62%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

OGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

OGEN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ORAGENICS INC

NYSEARCA:OGEN (12/18/2024, 4:53:09 PM)

After market: 0.62 +0.3 (+93.75%)

0.32

-0.02 (-4.48%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap3.91M

Analysts

Price Target

Short Float %

Short Ratio

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-383.66%
ROE	-648.76%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.17
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.93
Quick Ratio	1.93
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-36.18%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next YN/A

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ORAGENICS INC (OGEN)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens